The SMARCA4/SMARCA2 allosteric inhibitor, FHD-286, effectively suppressed the proliferation of a broad collection of patient-derived AML cells, promoted differentiation, and decreased tumor growth in vivo [125]. This evidence concerns the gene SMARCA2 and neoplasm.